Dialysis stocks jump on Ozempic kidney data
• Shares of dialysis providers jumped 3-12% as Ozempic data showed less effect on kidney disease than expected
• Investors believe Ozempic's benefits relate more to cardiac events rather than slowing kidney disease
• Potential for GLP-1 drugs to treat issues beyond diabetes has hit shares of bariatric surgery, food, and glucose monitoring firms
• Colorado's DaVita rose 8% and Fresenius Medical 12.3% in morning trade
• Baxter, which provides dialysis via its kidney care unit, also gained 2.5% amid the surge